Imagine a clinician assessing an herbal supplement or natural therapy for a patient. Without clear, structured product information, prescribing decisions can become complex and risk-prone. This article explores how clinicians can use Product Information (PI) resources, from official TGA documents through to specialist databases such as The Compendium, to support safer, evidence-informed decision-making in complementary and alternative medicine.
You will learn how structured drug data and decision-support tools may assist patient safety, support regulatory awareness, and improve prescribing confidence in integrative care.
Clinicians rely on accurate and up-to-date product information when making prescribing decisions.
In Australia, registered medicines included on the Australian Register of Therapeutic Goods (ARTG) have a Product Information (PI) document approved by the Therapeutic Goods Administration (TGA). A PI contains key clinical details such as composition, approved indications, dosage and administration, contraindications, precautions, and adverse effects. These documents are prepared by the sponsor and reviewed by the TGA as part of the registration process.
For complementary medicines, many products are listed medicines on the ARTG and may have more limited publicly available clinical information compared to registered medicines.
In this context, centralised databases may assist clinicians by bringing together structured product data in one location. Platforms such as The Compendium provide consolidated information on selected complementary and alternative medicines, including ingredient listings, available product formats, and supporting documentation where available.
Clinical value: Centralised access to structured product information may help reduce time spent searching across multiple sources and support more consistent review of product characteristics such as formulation details, quality documentation, and availability.
All therapeutic goods supplied in Australia must be included in the ARTG under the Therapeutic Goods Act 1989.
For registered medicines, TGA-approved PI documents provide standardised clinical information, including:
Clinicians can access PI documents through the ARTG database or TGA resources to verify prescribing details, including for prescription medicines and certain higher-risk therapies.
While complementary medicines may not always have a PI in the same format as registered medicines, structured product information tools may assist clinicians in reviewing formulation differences, particularly where multiple variants exist (for example, differing cannabinoid or herbal profiles).
Reliable clinical information on complementary medicines can be more limited compared to conventional medicines.
Australian Prescriber notes that information on complementary and alternative medicines may be less readily available, making evidence-based resources particularly important in clinical practice.
Clinicians may refer to a range of sources, including:
These references can help clinicians interpret available evidence on efficacy, safety, and potential risks.
For example, some herbal products have documented interaction profiles:
Clinical value: Evidence-based resources may assist clinicians in identifying known risks, assessing the strength of supporting evidence, and making more informed prescribing decisions.
Checking for interactions is an important step when patients are using supplements alongside prescription medicines.
Clinicians may use clinical decision-support tools such as MIMS or eMIMS, which include interaction checking functionality covering selected complementary medicines. Some platforms also incorporate dedicated herb–drug interaction modules.
Additional references include Natural Medicines interaction checkers and Australian Prescriber guidance on complementary medicine safety resources.
Clinical best practice: Using reputable interaction databases may help identify potential risks and support safer co-prescribing decisions.
All therapeutic goods supplied in Australia must comply with TGA regulatory requirements and include appropriate ARTG listing or registration details.
Complementary medicines are generally listed medicines and identified with an AUST L number, while registered medicines carry an AUST R number.
Some higher-risk medicines, including certain unapproved products such as medicinal cannabis accessed through the Special Access Scheme (SAS) or Authorised Prescriber (AP) pathways, require additional regulatory oversight.
Clinicians authorised under these schemes must comply with reporting obligations and prescribing conditions set by the TGA.
Structured product information systems may assist clinicians in reviewing formulation details and maintaining awareness of relevant regulatory requirements, although responsibility for compliance remains with the prescribing practitioner.
The TGA Authorised Prescriber (AP) and Special Access Scheme (SAS) frameworks enable access to specific unapproved therapeutic goods under defined conditions.
Clinicians working within these frameworks must ensure appropriate clinical justification and regulatory compliance.
Product information tools may assist by consolidating available product details, such as formulation type, cannabinoid profiles (where applicable), and dosing ranges, from sponsors or supporting literature.
This may help clinicians compare available product options within regulatory boundaries and clinical suitability considerations.
Integrative care focuses on combining conventional and complementary approaches where clinically appropriate, guided by available evidence and patient context.
Access to structured product information may support clinicians in discussing risks, benefits, and suitability of complementary therapies with patients.
For example, understanding known interactions between herbal medicines and anticoagulants may help clinicians provide more informed guidance to patients already taking prescription therapies.
Clinical value: Clear product data may support shared decision-making and more individualised treatment planning in integrative care settings.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Digital platforms that consolidate product information may support more efficient clinical workflows.
Some systems provide:
These tools may reduce the need to consult multiple fragmented sources and assist clinicians in accessing relevant product data more efficiently.
Complementary medicine evidence and regulation continue to evolve.
Clinicians are encouraged to stay informed through:
Regular engagement with updated evidence may support more informed prescribing decisions and awareness of emerging safety considerations.
Structured product information resources can support clinicians in making more informed decisions when prescribing complementary and alternative medicines.
By combining official TGA Product Information documents with evidence-based databases and clinical decision-support tools, practitioners may improve their understanding of product composition, safety considerations, and regulatory requirements.
This supports more consistent, evidence-informed integrative care and helps clinicians tailor treatment decisions to individual patient needs.
“*” indicates required fields
PRIVACY COLLECTION NOTICE
This Privacy Collection Notice describes how PHENIX HEALTH PTY LTD (ABN 22 607 822 266) (we, us or our) collects and handles your personal information when you make an enquiry with us. We collect personal information from you so that we can respond to your enquiry and for related purposes set out in our Privacy Policy, available on our website (or on request).
We may disclose this personal information to third parties, including our personnel, related entities, any third parties engaged by us and acting on our behalf and as otherwise set out in our Privacy Policy.
We store personal information in Australia. Where we disclose your personal information to third parties, those third parties may store, transfer or access personal information outside of Australia.
If you do not provide your personal information to us, it may affect our ability to do business with you.
Please see our Privacy Policy for more information about how we collect, store, use and disclose your personal information, including details about overseas disclosure, access, correction, how you can make a privacy-related complaint and our complaint-handling process.
If you have questions about our privacy practices, please contact us by email at: info@thecompendium.health. By providing your personal information to us, you agree to the collection, use, storage and disclosure of that information as described in this privacy collection notice.
